Cargando…
Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease
BACKGROUND: The objective of the study is to assess the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in patients with congenital heart diseases (CHDs) and control. PATIENTS AND METHODS: In this case-control study, sixty patients with CHD with ages of 1 month to 15 years a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995815/ https://www.ncbi.nlm.nih.gov/pubmed/27630387 http://dx.doi.org/10.4103/0300-1652.188353 |
_version_ | 1782449548515344384 |
---|---|
author | Noori, Noor Mohammad Moghaddam, Maryam Nakhaee Teimouri, Alireza Shahramian, Iraj Keyvani, Behrooz |
author_facet | Noori, Noor Mohammad Moghaddam, Maryam Nakhaee Teimouri, Alireza Shahramian, Iraj Keyvani, Behrooz |
author_sort | Noori, Noor Mohammad |
collection | PubMed |
description | BACKGROUND: The objective of the study is to assess the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in patients with congenital heart diseases (CHDs) and control. PATIENTS AND METHODS: In this case-control study, sixty patients with CHD with ages of 1 month to 15 years and thirty healthy subjects were assessed. All objects measured in height, weight, age, sex, and body mass index (BMI). Patients diagnosed by echocardiography and patients’ blood samples were 3 ml and taken in the catheterization laboratory through catheter and kept for 60 min at a room with normal temperature and separated serum has been held. All samples in compliance with the cold chain carried out to biochemistry laboratory and finally the levels of serum TNF-α and IL-6 were measured by Elisa Kit. Data were analyzed with Statistical Package for Social Sciences version 20. Nonparametric tests by considering 95% confidence interval were applied. RESULTS: The mean of age in cyanotic patients was 4.28 3.44 years, a cyanotic was 3.12 3.87 years and for the control group was 3.30 3.61 years. Comparison of TNF-α (Mann-Whitney U-test = 56.62, P < 0.001), IL-6 (Mann-Whitney U-test = 313.5, P < 0.001), right ventricular (RV) pressure (Mann-Whitney U-test = 27, P < 0.001), pulmonary artery (PA) pressure (Mann-Whitney U-test = 618, P = 0.015), and BMI (Mann-Whitney U-test = 214.5, P < 0.001) in the case and control groups resulted in significant differences. To compare TNF-α (Chi-square = 57.82, P < 0.001), IL-6 (Chi-square = 54.70, P < 0.001), RV pressure (Chi-square = 71.35, P < 0.001), PA pressure (Chi-square = 5.92, P = 00.052), oxygen saturation (Chi-square = 74.70, P < 0.001), and BMI (Chi-square = 34.90, P < 0.001) in cyanotic, acyanotic, and control groups resulted that there were significant differences between these three groups except PA pressure. CONCLUSION: The findings of this study showed that in patients with CHD, serum levels of TNF-α increased but IL-6 not changed when compared to control and this increase in necrosis tumoral factor-α would be related with hypoxia and remarkable left to right shunt and caused growth retardation in these patients. |
format | Online Article Text |
id | pubmed-4995815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-49958152016-09-14 Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease Noori, Noor Mohammad Moghaddam, Maryam Nakhaee Teimouri, Alireza Shahramian, Iraj Keyvani, Behrooz Niger Med J Original Article BACKGROUND: The objective of the study is to assess the levels of tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in patients with congenital heart diseases (CHDs) and control. PATIENTS AND METHODS: In this case-control study, sixty patients with CHD with ages of 1 month to 15 years and thirty healthy subjects were assessed. All objects measured in height, weight, age, sex, and body mass index (BMI). Patients diagnosed by echocardiography and patients’ blood samples were 3 ml and taken in the catheterization laboratory through catheter and kept for 60 min at a room with normal temperature and separated serum has been held. All samples in compliance with the cold chain carried out to biochemistry laboratory and finally the levels of serum TNF-α and IL-6 were measured by Elisa Kit. Data were analyzed with Statistical Package for Social Sciences version 20. Nonparametric tests by considering 95% confidence interval were applied. RESULTS: The mean of age in cyanotic patients was 4.28 3.44 years, a cyanotic was 3.12 3.87 years and for the control group was 3.30 3.61 years. Comparison of TNF-α (Mann-Whitney U-test = 56.62, P < 0.001), IL-6 (Mann-Whitney U-test = 313.5, P < 0.001), right ventricular (RV) pressure (Mann-Whitney U-test = 27, P < 0.001), pulmonary artery (PA) pressure (Mann-Whitney U-test = 618, P = 0.015), and BMI (Mann-Whitney U-test = 214.5, P < 0.001) in the case and control groups resulted in significant differences. To compare TNF-α (Chi-square = 57.82, P < 0.001), IL-6 (Chi-square = 54.70, P < 0.001), RV pressure (Chi-square = 71.35, P < 0.001), PA pressure (Chi-square = 5.92, P = 00.052), oxygen saturation (Chi-square = 74.70, P < 0.001), and BMI (Chi-square = 34.90, P < 0.001) in cyanotic, acyanotic, and control groups resulted that there were significant differences between these three groups except PA pressure. CONCLUSION: The findings of this study showed that in patients with CHD, serum levels of TNF-α increased but IL-6 not changed when compared to control and this increase in necrosis tumoral factor-α would be related with hypoxia and remarkable left to right shunt and caused growth retardation in these patients. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4995815/ /pubmed/27630387 http://dx.doi.org/10.4103/0300-1652.188353 Text en Copyright: © Nigerian Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Noori, Noor Mohammad Moghaddam, Maryam Nakhaee Teimouri, Alireza Shahramian, Iraj Keyvani, Behrooz Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
title | Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
title_full | Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
title_fullStr | Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
title_full_unstemmed | Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
title_short | Evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
title_sort | evaluation of serum level of tumor necrosis factor-alpha and interleukin-6 in patients with congenital heart disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995815/ https://www.ncbi.nlm.nih.gov/pubmed/27630387 http://dx.doi.org/10.4103/0300-1652.188353 |
work_keys_str_mv | AT noorinoormohammad evaluationofserumleveloftumornecrosisfactoralphaandinterleukin6inpatientswithcongenitalheartdisease AT moghaddammaryamnakhaee evaluationofserumleveloftumornecrosisfactoralphaandinterleukin6inpatientswithcongenitalheartdisease AT teimourialireza evaluationofserumleveloftumornecrosisfactoralphaandinterleukin6inpatientswithcongenitalheartdisease AT shahramianiraj evaluationofserumleveloftumornecrosisfactoralphaandinterleukin6inpatientswithcongenitalheartdisease AT keyvanibehrooz evaluationofserumleveloftumornecrosisfactoralphaandinterleukin6inpatientswithcongenitalheartdisease |